How much does ivonib (ivitinib) cost?

Ivosidenib (Ivosidenib) As an IDH1 inhibitor, Ivosidenib is specifically targeted at patients with acute myeloid leukemia (AML) who carry IDH1 gene mutations. By inhibiting the abnormal protein produced by the IDH1 gene mutation, ivonib can interfere with the growth and division of AML cells, thereby significantly slowing the progression of the disease.

The research and development process of avonib embodies the wisdom and efforts of scientists. Since the U.S. FDA first approved it in 2018 for the treatment of adult patients with relapsed or refractory AML with IDH1 mutations, ivosidenib has demonstrated its excellent therapeutic effects globally. In 2022, China's National Medical Products Administration (NMPA) also approved the new drug marketing application for ivonib, making it the first approved IDH1 inhibitor in China.

In clinical trials, ivonib demonstrated significant anti-tumor activity and good tolerability. A phase III randomized, double-blind, placebo-controlled trial in patients with newly diagnosed AML with IDH1 mutations showed that ivosidenib significantly improved overall survival and median complete response rate compared with placebo. This result not only proves the effectiveness of ivonib in the treatment of AML, but also provides the possibility of its application in other cancer types such as cholangiocarcinoma.

However, ivonib also has some potential adverse reactions, such as nausea, diarrhea, stomach pain, etc. Therefore, when using ivosidenib for treatment, close attention to the patient's physical condition and appropriate monitoring and care are required.

Currently, ivonib is available on the domestic market, but has not yet been included in medical insurance. Avosidenib sold in China is an original research drug. Each box contains 250mg*60 tablets and sells for more than 90,000 yuan. Considering its high price, patients may consider looking at versions available overseas. Avosidenib marketed overseas is divided into original research version and generic version. The original research version is priced at nearly 260,000 yuan, while the generic version launched by Lucius in Laos is more affordable, about 6,800 yuan. If you have more questions, it is recommended to consult a professional overseas medical consultant. In summary, as a new anti-cancer drug, ivonib provides a new treatment option for leukemia patients.